XML 64 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 29, 2017
USD ($)
Target
Oct. 31, 2017
USD ($)
$ / shares
shares
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock, value of shares issued in connection with agreement         $ 6,909    
Deferred revenue         94,063 $ 212,315 $ 301,326
Amgen Inc | EGFR Products              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         9,700    
Collaboration and License Agreement | Amgen Inc              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Upfront payment received $ 40,000 $ 40,000          
Common stock, shares issuable under agreement | shares   1,156,069          
Common stock, shares issuable under agreement, price per share | $ / shares   $ 17.3          
Common stock, value of shares issued in connection with agreement   $ 20,000          
Number of targets selected | Target 1            
Number of additional collaboration target | Target 2            
Total transaction price $ 51,200            
Portion of transaction price allocated to premium on sale of common stock 500            
Estimated fair value of products 10,700            
Collaboration and License Agreement | Amgen Inc | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contingent payments payable 203,000            
Collaboration and License Agreement | Amgen Inc | EGFR Products              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price 46,400            
Estimated research service period     7 years 8 years      
Deferred revenue         $ 9,700 $ 12,800  
Collaboration and License Agreement | Amgen Inc | EGFR Products | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contingent milestone payments receivable $ 460,000            
Percentage share of profit and losses 50.00%            
Collaboration and License Agreement | Amgen Inc | Amgen Products | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contingent milestone payments receivable $ 950,000            
Number of targets | Target 3            
Collaboration and License Agreement | Amgen Inc | Amgen Other Products              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price $ 4,800            
Estimated research service period 6 years            
Revenue recognition upon performance obligation $ 4,800            
Sublicense Agreement | Amgen Inc | Maximum | UC Regents              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Sublicense payment percentage 7.50%